-
Bristol-Myers' Trash is Gilead Sciences' Treasure
Friday, August 24, 2012 - 9:16am | 584Amid a track record of continued success and secured patents, Gilead Sciences (NASDAQ: GILD) is once again headlining the infectious disease realm with a new hepatitis C offering despite news that Bristol-Myers Squibb (NYSE: BMY) has discontinued its experimental therapy trials following a patient...